智通财经APP获悉，Piper Sandler将Organon(OGN.US)的评级从“增持”下调至“减持”，并将目标股价从 18 美元下调至 5 美元。此次行动是在审计委员会对公司进行调查之后采取的，该调查揭露了公司在其避孕产品“Nexplanon”方面存在重大内部控制缺陷，导致 2022 年、2024 年和 2025 年的财务报表出现错误陈述。周一，该公司股价收跌约23%。
此次评级下调表明，Piper Sandler认为Organon的复苏之路漫长，这主要是由于需要恢复内部控制和投资者信心。分析师们还提醒投资者，鉴于当前的不确定性以及该公司扭亏为盈的过程将会既漫长又充满挑战，风险和波动性可能会加剧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.